Astera Labs Reports Third Quarter 2026 Financial Results
Nine-month operating cash flow rose to $341.477 million from $224.041 million a year earlier.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Astera Labs (Nasdaq: ALAB) reported third-quarter 2026 revenue of $584.9 million, up 154% year over year, with Scorpio leading growth. Revenue rose 49% sequentially for the quarter ended September 30. Scorpio became the largest product family by revenue as its X-Series fabric switches reached high-volume production.
GAAP net income reached $182.944 million, or $0.99 per diluted share, versus $91.114 million and $0.50 a year earlier. GAAP operating income was $179.056 million, with a 30.6% operating margin and 72.3% gross margin.
Astera Labs expects fourth-quarter revenue of $730 million to $750 million and GAAP diluted earnings per share of approximately $1.13 to $1.17. Its outlook includes approximately 72% GAAP gross margin and approximately $273 million to $279 million in GAAP operating expenses. The portfolio expanded with Aries 7, Leo memory controllers and the Orion rack-scale reference architecture.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointQ3 revenue of $584.9 million rose 49% sequentially and 154% year over year.
- Major point. Forward-looking: it has not happened yet and may not happen.Q4 revenue outlook of $730 million to $750 million exceeds Q3 revenue.
- Moderate pointScorpio X-Series reached high-volume production, making Scorpio the largest product family by revenue.
- Moderate pointQ3 GAAP operating income of $179.056 million increased from $55.406 million a year earlier.
- Moderate pointQ3 GAAP net income of $182.944 million increased from $91.114 million a year earlier.
- Moderate pointQ3 GAAP diluted EPS of $0.99 increased from $0.50 a year earlier.
- Moderate pointNine-month operating cash flow of $341.477 million increased from $224.041 million a year earlier.
10 minor points
- Minor pointQ3 GAAP operating margin was 30.6%, with gross margin of 72.3%.
- Minor point. Forward-looking: it has not happened yet and may not happen.Q4 GAAP diluted EPS outlook is approximately $1.13 to $1.17, above Q3's $0.99.
- Minor pointNine-month revenue of $1,285.660 million increased from $581.942 million a year earlier.
- Minor pointNine-month GAAP operating income of $330.137 million increased from $106.465 million a year earlier.
- Minor pointNine-month GAAP net income of $416.342 million increased from $174.152 million a year earlier.
- Minor pointNine-month GAAP diluted EPS of $2.28 increased from $0.97 a year earlier.
- Minor pointCash and equivalents reached $209.396 million at September 30, versus $167.611 million at December 31, 2025.
- Minor pointMarketable securities reached $1,168.847 million at September 30, versus $1,021.205 million at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Aries 7 sampling is expected to begin in Q4 2026 for select customers.
- Minor point. Forward-looking: it has not happened yet and may not happen.Orion reference and system designs are on track for availability through OEM and ODM partners beginning Q1 2027.
Negative
- Moderate pointQ3 GAAP operating expenses of $243.696 million increased from $120.406 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Q4 GAAP operating expenses are expected at approximately $273 million to $279 million, above Q3.
- Minor point. Forward-looking: it has not happened yet and may not happen.Q4 GAAP gross margin is expected at approximately 72%, versus Q3's 72.3%.
- Minor point. Forward-looking: it has not happened yet and may not happen.Q4 GAAP tax rate is expected at approximately 20%.
- Minor point. Forward-looking: it has not happened yet and may not happen.Q4 weighted-average diluted shares are expected at approximately 187 million, versus 184.077 million in Q3.
6 minor points
- Minor pointQ3 income tax provision was $9.083 million, versus a $24.252 million benefit a year earlier.
- Minor pointReceivables used $201.245 million of cash in the first nine months, versus $4.089 million a year earlier.
- Minor pointInventory used $146.173 million of cash in the first nine months, versus $7.106 million a year earlier.
- Minor pointNine-month property and equipment purchases of $73.363 million increased from $18.855 million a year earlier.
- Minor pointBusiness combinations required $69.214 million in nine-month payments, net of cash acquired.
- Minor pointNine-month stock-based compensation of $195.495 million increased from $118.659 million a year earlier.
News Explained
The disclosed stock-based-compensation add-back is $82,590 thousand, the stated bridge between GAAP and non-GAAP operating income.
Astera Labs’ completed Q3 2026 results report quarter-end cash and cash equivalents of
The company says non-GAAP measures supplement, rather than replace, GAAP results; its reconciliation adds back
Details
Market Reaction – ALAB
On Nov 3, the day this news came out, the latest delayed price for ALAB is 1.12% below the previous close. Argus tracked a peak move of +1.1% during the session. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner has recorded 43 alerts for this stock so far that day. The latest delayed price is $231.01.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $584.9 million
- Q3 FY2026; up 49% QoQ and 154% year-over-year
- GAAP gross margin
- 72.3%
- Q3 FY2026
- GAAP operating income
- $179.1 million
- Q3 FY2026
- GAAP net income
- $182.9 million
- Q3 FY2026
- GAAP diluted EPS
- $0.99
- Q3 FY2026
- Revenue outlook
- $730 million to $750 million
- Q4 FY2026
- GAAP diluted EPS outlook
- $1.13 to $1.17
- Q4 FY2026
Previous Earnings Reports
-
Q2 results set a specific Q3 revenue-guidance benchmark for the current reported quarter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gaap financial
non-gaap financial
pcie technical
cxl technical
ddr5 technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Record quarterly revenue of
$584.9 million , up49% QoQ and up154% year-over-year - Scorpio™ fabric switches became the company's largest product family, led by volume production of the Scorpio X-Series 320-lane fabric switch
- Portfolio expanded across memory, optical and copper signal conditioning, and rack-scale AI platforms with Leo 2 and Leo X-Series, Aries 7 and Orion
SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced financial results for the third quarter of fiscal year 2026, ended September 30, 2026.
“Astera Labs delivered outstanding Q3 2026 results, with record quarterly revenue of
Third Quarter of Fiscal 2026 Financial Highlights
GAAP Financial Results:
- Revenue of
$584.9 million , up49% sequentially and up154% year-over-year - GAAP gross margin of
72.3% - GAAP operating income of
$179.1 million - GAAP operating margin of
30.6% - GAAP net income of
$182.9 million - GAAP diluted net income per share of
$0.99
Non-GAAP Financial Results (1):
- Non-GAAP gross margin of
72.4% - Non-GAAP operating income of
$261.6 million - Non-GAAP operating margin of
44.7% - Non-GAAP net income of
$243.4 million - Non-GAAP diluted net income per share of
$1.32
____________
(1) See “Reconciliation of GAAP to Non-GAAP Financial Measures” table included below.
Q3 2026 and Recent Business Highlights
- Announced Aries 7, the industry’s first and broadest PCIe® 7 signal conditioning portfolio, spanning Smart Retimers, Smart Redrivers, Smart Cable Modules, Smart Optical Drivers, and Smart Optical Transimpedance Amplifiers (TIAs). The expanded portfolio extends reach from centimeters of PCB trace to 50+ meters over optical cables spanning multiple racks and includes optical connectivity solutions purpose-built for near-packaged optics (NPO) and linear pluggable optics (LPO) applications. Aries 7 Smart Retimers and Smart Redrivers support the OCP Signal Conditioner Standard Footprint, allowing customers to select different signal conditioners without redesigning the board. Aries 7 products are expected to begin sampling in Q4 2026 to select hyperscale, OEM, and NPO customers.
- Unveiled Orion, a compute-agnostic rack-scale reference architecture that allows customers to choose their own GPU and CPU. Orion comprises six production-grade reference designs—spanning rack, compute tray, fabric tray, memory tray, link board, and compute board—and its high-radix 320-lane PCIe switch fabric is designed to scale from 8 to 160 accelerators per pod while helping the same accelerator extract more tokens per second across AI inference workloads. All designs are integrated with COSMOS Rack Manager and COSMOS Fabric Manager orchestration software for management, fleet-wide telemetry and diagnostics. Orion is designed primarily for neocloud and enterprise customers building AI inference capacity, and rack reference and system designs are on track for availability through Astera Labs’ OEM and ODM partners beginning in Q1 2027.
- Expanded the Leo Smart Memory Controller™ family with three new memory connectivity solutions—Leo X-Series and the Leo 2 E-Series and P-Series—extending the portfolio across direct fabric-attached GPU memory, CPU-attached expansion, and pooled memory architectures. Paired with Scorpio X-Series Fabric Switches, Leo X-Series enables fabric-attached memory for long-context, KV-cache-intensive workloads, improving inference performance with up to
62% faster time-to-first-token and up to22% more tokens per second (as measured by the company’s internal testing). The new Leo 2 E-Series and P-Series support CPU-attached DDR4 and DDR5 memory expansion with PCIe® 6 and CXL® 3.2 support, and double memory bandwidth and capacity versus the previous generation. - Showcased the expanded Aries and Orion families at the 2026 Open Compute Project (OCP) Global Summit in San Jose, including a powered Orion rack featuring interchangeable, pre-validated compute trays with different CPU and accelerator configurations and live demonstrations of the Scorpio X-Series 320-lane Smart Fabric Switch with Hypercast™ and In-Network Compute, the Leo X-Series Smart Memory Controller, and PCIe 7 copper and optical signal conditioning.
Fourth Quarter of Fiscal 2026 Financial Outlook
Based on current business trends and conditions, Astera Labs estimates the following:
GAAP Financial Outlook:
- Revenue within a range of
$730 million to$750 million - GAAP gross margin of approximately
72% - GAAP operating expenses within a range of approximately
$273 million to$279 million - GAAP tax rate of approximately
20% - GAAP diluted net income per share of approximately
$1.13 t o$1.17 on weighted-average diluted shares outstanding of approximately 187 million
Non-GAAP Financial Outlook(2):
- Non-GAAP gross margin of approximately
72% - Non-GAAP operating expenses within a range of approximately
$194 million to$200 million - Non-GAAP tax rate of approximately
12% - Non-GAAP diluted net income per share of approximately
$1.62 t o$1.66 on weighted-average diluted shares outstanding of approximately 187 million
_____________
(2) See “Reconciliation of GAAP to Non-GAAP Outlook” table included below.
Earnings Webcast and Conference Call
Astera Labs will host a conference call to review its financial results for the third quarter of 2026 and to discuss its financial outlook today at 1:30 p.m. Pacific Time. Interested parties may join the conference call by dialing 1-833-461-5787 and using conference ID 751 181 378. The call will also be webcast and can be accessed at the Astera Labs website at https://ir.asteralabs.com/. The webcast will be recorded and available for replay on the company’s website for the next six months.
Discussion of Non-GAAP Financial Measures
We use certain non-GAAP financial measures, including those concerning our financial outlook, to supplement the performance measures in our consolidated financial statements, which are presented in accordance with GAAP. A reconciliation of these non-GAAP measures to the closest GAAP measures can be found later in this release. The timing and impact of any adjustments to arrive at the corresponding GAAP financial measures concerning our financial outlook are inherently dependent on future events that are typically uncertain or that may be outside of our control. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, and non-GAAP diluted net income per share. We use these non-GAAP financial measures for financial and operational decision-making and as a means to assist us in evaluating period-to-period comparisons. By excluding certain items that may not be indicative of our recurring core operating results, we believe that non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, and non-GAAP diluted net income per share provide meaningful supplemental information regarding our performance. Accordingly, we believe these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by our institutional investors and the analyst community to help them analyze the health of our business. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
We adjust the following items from one or more of our non-GAAP financial measures:
Stock-based compensation expense
We exclude non-cash stock-based compensation expense from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, companies calculate non-cash stock-based compensation expense using a variety of valuation methodologies and subjective assumptions. Moreover, stock-based compensation expense is a non-cash charge that can vary significantly from period to period for reasons that are unrelated to our core operating performance, and therefore excluding this item provides investors and other users of our financial information with information that allows meaningful comparisons of our business performance across periods.
Acquisition-related costs
We exclude acquisition-related costs incurred in connection with our acquisitions, which we generally would not have otherwise incurred in the periods presented as part of our continuing operations. Acquisition-related costs include certain incremental expenses incurred to effect a business combination such as third-party costs: advisory, legal, accounting, valuation, and other professional fees. We believe that providing the non-GAAP measures excluding these costs assists our investors because such costs are not reflective of our ongoing operating results.
Other
We exclude other adjustments, including non-cash fair value adjustments related to equity investments without readily determinable fair values. These investments are measured at cost and adjusted for observable price changes or impairment on a nonrecurring basis only upon the occurrence of certain events. Accordingly, these adjustments are not indicative of our core operating performance.
Income tax effect
This represents the impact of the non-GAAP adjustments on an after-tax basis and one-off discrete tax adjustments that are unrelated to our core operating performance in connection with the presentation of non-GAAP net income and non-GAAP diluted net income per share. This approach is designed to enhance investors’ ability to understand the impact of our non-GAAP tax expense on our current operations, provide improved modeling accuracy, and substantially reduce fluctuations caused by GAAP to non-GAAP adjustments.
Cautionary Note Regarding Forward-Looking Statements
This press release and the accompanying oral presentation contain forward-looking statements based on Astera Labs' current expectations. The words “accelerating,” “advance,” “ahead,” “aim,” “anticipate,” “beginning,” “believe,” “built to,” “can,” “capabilities,” “coming,” “commence,” “committed,” “confidence,” “continue,” “could,” “deliver,” “designed,” “drive,” “early stages,” “enable,” “estimates," “expanding,” “expect," “forecasting,” “forthcoming,” “forward,” “future,” “goal,” “going forward,” “growth,” “guidance,” “intend," “interest,” “journey,” “long-term,” “look,” “may,” “mission,” “momentum,” “multi-year,” “next,” “on track,” “opportunity,” “outlook,” “paths,” “plan,” “poised,” “position,” “potential,” “progressing,” “project,” “proliferate,” “proposed,” “prospects,” “provide,” “pursuing,” “ramp,” “represent,” “roadmap,” “should,” “strategy,” “targeted,” “track,” “trajectory,” “trends,” “upcoming,” “upside,” “ultimately,” “vectors,” “vision,” “well positioned,” “will,” “would,” and similar phrases as they relate to Astera Labs, as well as any references to future periods, are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Astera Labs as of November 3, 2026, and are subject to various assumptions, beliefs, risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements include, but are not limited to, statements regarding market trends, dynamics and expectations (including cloud and AI infrastructure and connectivity market trends and the industry’s build-out); our and our ultimate customers’ future demand, product purchases, deployment of systems incorporating our products, business, operating results, cash flow, financial position, outlook and guidance (and any underlying drivers), including for the fourth quarter of fiscal 2026; our business strategy, plans and market, revenue or other forms of opportunities, our absolute or relative market share or growth profile or rate and our timing, diversification and ability to further build upon our revenue base, expand our product offerings, portfolio and features or performance, increase and service our market opportunity (including the timing and extent of such market opportunities), remain at the forefront of an AI infrastructure transformation, and scale or expand our connectivity platform; our objectives or strategies for future operations (such as our optical, custom solutions and rack-scale platform businesses), organizational investments and changes, and the drivers, timing and impacts associated therewith; our pre-production, production, development, shipping/shipments and delivery of (including timing and customers), activity, applications and demand for, availability of, as well as absolute and relative revenue, growth (including the drivers), pricing, ramping and roadmap (e.g., optical, Leo and Orion) for, existing, new, growing or enhanced (whether technologically or otherwise) products or software, including the high volume deployment of Scorpio X-Series solutions, the expansion of our Scorpio P-Series customer base, the sampling and availability of our Aries 7 portfolio, the availability of Orion rack reference and system designs through our OEM and ODM partners, the adoption of our expanded Leo portfolio, and additional growth catalysts across our Scorpio, Aries, Taurus and Leo portfolios, and the comparative capabilities, performance and results of those products or software for our customers; the benefits, timing, impact, proliferation and customer adoption of different connectivity standards and demands; the design wins at and diversification, activity, engagements and expectations of our customers; the plans and potential success of our announced and ongoing collaborations, partnerships and strategic relationships, including our warrant agreement with Amazon and our collaborations with AMD, Intel and NVIDIA; the ability of UALink 2.0 to provide for a purpose-built AI compute fabric capable of scaling with industry needs over time and the timing of any initial programs; our competitive positioning and the impacts thereof; our research and development, technology and strategic IP plans; the strategies associated with, investments in and size of our team, as well as the associated impacts; and future industry and macroeconomic conditions, events and trends such as in cloud and AI infrastructure as well as our preparedness and solutions for them.
A variety of risks and factors that are beyond our control could cause actual results to differ materially from those in the forward-looking statements including, without limitation: the competitive and cyclical nature of the semiconductor industry; the concentration of our customer base; the changes in demand for AI; the macroeconomic and/or geopolitical environment, including economic uncertainty and volatility in the capital markets; risks that demand for our products and the supply chain may be adversely affected, including by the imposition of tariffs by the United States or any other jurisdiction and any corresponding retaliatory tariffs, changes in political policies, military conflict (such as between Russia/Ukraine and in Israel, Iran and the Middle East), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with managing international activities (including trade barriers, particularly with respect to China); our ability to successfully complete acquisitions and to integrate newly acquired businesses and offerings; absence of long-term commitments from customers; risks that Astera Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; stock price volatility; information technology risks, including cybersecurity risks such as cyber-attacks against Astera Labs' products and its networks; and other risks and uncertainties that are detailed under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on February 20, 2026, and in subsequent Quarterly Reports on Form 10-Q filed with the SEC and the other SEC filings and reports Astera Labs may make from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor(s) may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not unduly rely on any of the forward-looking statements. Astera Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
About Astera Labs
Astera Labs (Nasdaq: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, NVLink Fusion, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up and scale-out connectivity. The company's custom connectivity solutions business complements its standards-based portfolio, enabling customers to deploy tailored architectures to meet their unique infrastructure requirements. Discover more at www.asteralabs.com.
| ASTERA LABS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) | |||||||
| As of | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 209,396 | $ | 167,611 | |||
| Marketable securities | 1,168,847 | 1,021,205 | |||||
| Accounts receivable, net | 284,253 | 83,202 | |||||
| Inventory | 200,893 | 58,979 | |||||
| Prepaid expenses and other current assets | 91,830 | 31,033 | |||||
| Total current assets | 1,955,219 | 1,362,030 | |||||
| Property and equipment, net | 170,713 | 92,038 | |||||
| Goodwill | 91,557 | 19,015 | |||||
| Other assets | 82,844 | 58,740 | |||||
| Total assets | $ | 2,300,333 | $ | 1,531,823 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 96,828 | $ | 42,362 | |||
| Accrued expenses and other current liabilities | 146,752 | 90,680 | |||||
| Total current liabilities | 243,580 | 133,042 | |||||
| Other liabilities | 57,285 | 35,147 | |||||
| Total liabilities | 300,865 | 168,189 | |||||
| Stockholders’ equity | |||||||
| Common stock | 17 | 17 | |||||
| Additional paid-in capital | 1,585,959 | 1,348,969 | |||||
| Accumulated other comprehensive (loss) income | (13,188 | ) | 4,310 | ||||
| Retained earnings | 426,680 | 10,338 | |||||
| Total stockholders’ equity | 1,999,468 | 1,363,634 | |||||
| Total liabilities and stockholders’ equity | $ | 2,300,333 | $ | 1,531,823 | |||
| ASTERA LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Revenue | $ | 584,899 | $ | 392,400 | $ | 230,575 | $ | 1,285,660 | $ | 581,942 | ||||||
| Cost of revenue | 162,147 | 104,833 | 54,763 | 340,200 | 141,156 | |||||||||||
| Gross profit | 422,752 | 287,567 | 175,812 | 945,460 | 440,786 | |||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 170,957 | 135,898 | 78,928 | 432,489 | 210,206 | |||||||||||
| Sales and marketing | 37,432 | 26,372 | 19,359 | 85,703 | 59,670 | |||||||||||
| General and administrative | 35,307 | 36,049 | 22,119 | 97,131 | 64,445 | |||||||||||
| Total operating expenses | 243,696 | 198,319 | 120,406 | 615,323 | 334,321 | |||||||||||
| Operating income | 179,056 | 89,248 | 55,406 | 330,137 | 106,465 | |||||||||||
| Interest and other income | 12,971 | 13,577 | 11,456 | 38,129 | 32,773 | |||||||||||
| Income before income taxes | 192,027 | 102,825 | 66,862 | 368,266 | 139,238 | |||||||||||
| Income tax (provision) benefit | (9,083 | ) | 50,263 | 24,252 | 48,076 | 34,914 | ||||||||||
| Net income | $ | 182,944 | $ | 153,088 | $ | 91,114 | $ | 416,342 | $ | 174,152 | ||||||
| Net income per share: | ||||||||||||||||
| Basic | $ | 1.05 | $ | 0.89 | $ | 0.54 | $ | 2.41 | $ | 1.05 | ||||||
| Diluted | $ | 0.99 | $ | 0.83 | $ | 0.50 | $ | 2.28 | $ | 0.97 | ||||||
| Weighted-average shares used in calculating net income per share: | ||||||||||||||||
| Basic | 174,126 | 172,378 | 167,436 | 172,423 | 165,365 | |||||||||||
| Diluted | 184,077 | 183,340 | 180,631 | 182,871 | 178,961 | |||||||||||
| ASTERA LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 416,342 | $ | 174,152 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities | ||||||||
| Stock-based compensation | 195,495 | 118,659 | ||||||
| Depreciation and amortization | 12,681 | 3,983 | ||||||
| Warrants contra revenue | 30,397 | 4,016 | ||||||
| Accretion of discounts on marketable securities | (3,426 | ) | (6,278 | ) | ||||
| Other, net | 7,312 | 2,521 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (201,245 | ) | (4,089 | ) | ||||
| Inventory | (146,173 | ) | (7,106 | ) | ||||
| Prepaid expenses and other assets | (51,767 | ) | (56,760 | ) | ||||
| Accounts payable | 38,814 | (1,088 | ) | |||||
| Accrued expenses and other liabilities | 43,047 | (3,969 | ) | |||||
| Net cash provided by operating activities | 341,477 | 224,041 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (73,363 | ) | (18,855 | ) | ||||
| Purchases of marketable securities | (509,927 | ) | (664,432 | ) | ||||
| Sales and maturities of marketable securities | 348,213 | 515,109 | ||||||
| Payments for business combinations, net of cash acquired | (69,214 | ) | — | |||||
| Other investing activities | (2,500 | ) | (500 | ) | ||||
| Net cash used in investing activities | (306,791 | ) | (168,678 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from exercises of stock options | 802 | 1,730 | ||||||
| Proceeds from employee stock purchase plan | 6,294 | 4,345 | ||||||
| Net cash provided by financing activities | 7,096 | 6,075 | ||||||
| Net increase in cash, cash equivalents, and restricted cash | 41,782 | 61,438 | ||||||
| Cash, cash equivalents, and restricted cash | ||||||||
| Beginning of the period | 167,684 | 80,044 | ||||||
| End of the period | $ | 209,466 | $ | 141,482 | ||||
| ASTERA LABS, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (Unaudited) (In thousands, except percentages and per share amounts) | ||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||
| GAAP gross profit | $ | 422,752 | $ | 287,567 | $ | 175,812 | $ | 945,460 | $ | 440,786 | ||||||||||
| Stock-based compensation expense | 890 | 1,692 | 379 | 3,081 | 694 | |||||||||||||||
| Non-GAAP gross profit | $ | 423,642 | $ | 289,259 | $ | 176,191 | $ | 948,541 | $ | 441,480 | ||||||||||
| GAAP gross margin | 72.3 | % | 73.3 | % | 76.2 | % | 73.5 | % | 75.7 | % | ||||||||||
| Stock-based compensation expense | 0.2 | 0.4 | 0.2 | 0.2 | 0.1 | |||||||||||||||
| Non-GAAP gross margin(1) | 72.4 | % | 73.7 | % | 76.4 | % | 73.8 | % | 75.9 | % | ||||||||||
| GAAP operating income | $ | 179,056 | $ | 89,248 | $ | 55,406 | $ | 330,137 | $ | 106,465 | ||||||||||
| Stock-based compensation expense | 82,590 | 63,992 | 40,739 | 195,495 | 118,659 | |||||||||||||||
| Acquisition-related costs(2) | — | 232 | — | 1,213 | — | |||||||||||||||
| Non-GAAP operating income | $ | 261,646 | $ | 153,472 | $ | 96,145 | $ | 526,845 | $ | 225,124 | ||||||||||
| GAAP operating margin | 30.6 | % | 22.7 | % | 24.0 | % | 25.7 | % | 18.3 | % | ||||||||||
| Stock-based compensation expense | 14.1 | 16.3 | 17.7 | 15.2 | 20.4 | |||||||||||||||
| Acquisition-related costs(2) | — | 0.1 | — | 0.1 | — | |||||||||||||||
| Non-GAAP operating margin | 44.7 | % | 39.1 | % | 41.7 | % | 41.0 | % | 38.7 | % | ||||||||||
| GAAP net income | $ | 182,944 | $ | 153,088 | $ | 91,114 | $ | 416,342 | $ | 174,152 | ||||||||||
| Stock-based compensation expense | 82,590 | 63,992 | 40,739 | 195,495 | 118,659 | |||||||||||||||
| Acquisition-related costs(2) | — | 232 | — | 1,213 | — | |||||||||||||||
| Other(3) | — | (1,500 | ) | — | (1,500 | ) | — | |||||||||||||
| Income tax effect(4) | (22,134 | ) | (69,996 | ) | (43,627 | ) | (112,266 | ) | (66,935 | ) | ||||||||||
| Non-GAAP net income | $ | 243,400 | $ | 145,816 | $ | 88,226 | $ | 499,284 | $ | 225,876 | ||||||||||
| Net income per share attributable to common stockholders: | ||||||||||||||||||||
| GAAP - basic | $ | 1.05 | $ | 0.89 | $ | 0.54 | $ | 2.41 | $ | 1.05 | ||||||||||
| GAAP - diluted | $ | 0.99 | $ | 0.83 | $ | 0.50 | $ | 2.28 | $ | 0.97 | ||||||||||
| Non-GAAP - diluted | $ | 1.32 | $ | 0.80 | $ | 0.49 | $ | 2.73 | $ | 1.26 | ||||||||||
| Weighted average shares used to compute net income per share attributable to common stockholders: | ||||||||||||||||||||
| GAAP - basic | 174,126 | 172,378 | 167,436 | 172,423 | 165,365 | |||||||||||||||
| GAAP - diluted | 184,077 | 183,340 | 180,631 | 182,871 | 178,961 | |||||||||||||||
____________________
(1) Total may not sum due to rounding.
(2) Acquisition-related costs included certain incremental expenses incurred to effect a business combination such as third-party costs: advisory, legal, accounting, valuation, and other professional fees.
(3) Other included non-cash and nonrecurring fair value adjustments on equity investments without readily determinable fair values.
(4) Income tax effect is calculated based on the tax laws in the jurisdictions in which we operate and is calculated to exclude the impact of stock-based compensation expense and one-off discrete tax adjustments that are unrelated to our core operating performance. For the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, the non-GAAP tax rate was approximately
| ASTERA LABS, INC. RECONCILIATION OF GAAP TO NON-GAAP OUTLOOK (Unaudited) (In millions, except percentages and per share amounts) | ||||||||
| Outlook for Three Months Ending December 31, 2026 | ||||||||
| Low | High | |||||||
| GAAP gross margin | 72 | % | 72 | % | ||||
| Stock-based compensation expense | — | — | ||||||
| Non-GAAP gross margin | 72 | % | 72 | % | ||||
| GAAP operating expenses | $ | 273 | $ | 279 | ||||
| Stock-based compensation expense | (79 | ) | (79 | ) | ||||
| Non-GAAP operating expenses | $ | 194 | $ | 200 | ||||
| GAAP tax rate | 20 | % | 20 | % | ||||
| Income tax effect | (8 | ) | (8 | ) | ||||
| Non-GAAP tax rate | 12 | % | 12 | % | ||||
| GAAP net income per share - diluted | $ | 1.13 | $ | 1.17 | ||||
| Stock-based compensation expense | 0.43 | 0.43 | ||||||
| Income tax effect | 0.06 | 0.06 | ||||||
| Non-GAAP net income per share - diluted | $ | 1.62 | $ | 1.66 | ||||
| ASTERA LABS, INC. SUPPLEMENTAL FINANCIAL INFORMATION STOCK-BASED COMPENSATION EXPENSE (Unaudited) (In thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||
| Cost of revenue | $ | 890 | $ | 1,692 | $ | 379 | $ | 3,081 | $ | 694 | |||||
| Research and development | 49,395 | 36,413 | 21,711 | 115,212 | 58,749 | ||||||||||
| Sales and marketing | 19,678 | 11,419 | 9,361 | 40,989 | 30,874 | ||||||||||
| General and administrative | 12,627 | 14,468 | 9,288 | 36,213 | 28,342 | ||||||||||
| Total stock-based compensation expense | $ | 82,590 | $ | 63,992 | $ | 40,739 | $ | 195,495 | $ | 118,659 | |||||
IR CONTACT: Leslie Green
leslie.green@asteralabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Astera Labs' third-quarter 2026 revenue and earnings?
Astera Labs reported $584.9 million in revenue and GAAP diluted earnings per share of $0.99 for the quarter ended September 30, 2026. Revenue increased 49% sequentially and 154% year over year. GAAP net income was $182.944 million, compared with $91.114 million a year earlier.
What is Astera Labs' fourth-quarter 2026 outlook?
Astera Labs expects revenue of $730 million to $750 million and GAAP diluted earnings per share of approximately $1.13 to $1.17. Its outlook includes approximately 72% GAAP gross margin, approximately $273 million to $279 million in GAAP operating expenses, and approximately 187 million weighted-average diluted shares.
When will Astera Labs' Aries 7 and Orion designs become available?
Astera Labs expects Aries 7 sampling in Q4 2026 for select hyperscale, original equipment manufacturer and near-packaged optics customers, with Orion reference and system designs on track for availability beginning Q1 2027. Orion availability is through original equipment manufacturer and original design manufacturer partners.